🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Deborah Watson‐Jones

University of London

ORCID: 0000-0001-6247-1746

Also affiliated with London School of Hygiene & Tropical Medicine, Mwanza Intervention Trials Unit, National Institute for Medical Research

MedicineSocial Sciences

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 14 papers. Top paper: “Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial”.

Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial

The Lancet Global Health(2022)10.1016/s2214-109x(22)00309-6

N/A

4.4DataRank · unranked

117 citations

John Changalucha, Hilary Whitworth, Lígia A. Pinto, Paul Mutani, Jackton Indangasi +18 more

Comparing one dose of HPV vaccine in girls aged 9–14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial

The Lancet Global Health(2022)10.1016/s2214-109x(22)00306-0

N/A

3.1DataRank · unranked

70 citations

Troy J. Kemp, Aimée R. Kreimer, Partha Basu, John Changalucha, Allan Hildesheim +14 more

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial

The Lancet Infectious Diseases(2021)10.1016/s1473-3099(21)00125-0

N/A

1.7DataRank · unranked

95 citations

Daniela Manno, Muhammed O. Afolabi, Babajide Keshinro, Viki Bockstal, Baimba Rogers +87 more

A dose-reduction HPV vaccine immunobridging trial of two HPV vaccines among adolescent girls in Tanzania (the DoRIS trial) – Study protocol for a randomised controlled trial

Contemporary Clinical Trials(2021)10.1016/j.cct.2021.106266

N/A

0.841DataRank · unranked

25 citations

Hilary Whitworth, John Changalucha, Lígia A. Pinto, Joakim Dillner, Saidi Kapiga +6 more

Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults

Clinical Infectious Diseases(2023)10.1093/cid/ciad693

N/A

0.671DataRank · unranked

16 citations

Ken Liu, Édouard Lhomme, Julie Blie, John McCullough, Matthew Onorato +90 more

Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries

Trials(2021)10.1186/s13063-021-05035-9

N/A

0.630DataRank · unranked

18 citations

Édouard Lhomme, Mark Kieh, Abdoul Habib Béavogui, Stephen B. Kennedy, Seydou Doumbia +91 more

Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational Study

Vaccines(2024)10.3390/vaccines12020210

N/A

0.348DataRank · unranked

7 citations

Andrew J. Pollard, Catherine Schmidt‐Mutter, Fabrice Lainé, George PrayGod, Hannah Kibuuka +13 more

Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratory

EBioMedicine(2023)10.1016/j.ebiom.2023.104562

N/A

0DataRank · unranked

10 citations

Houreratou Barry, Mark Kieh, Zacchaeus Anywaine, Baimba Rogers, Seydou Doumbia +22 more

Prevalence of malaria and helminth infections in rural communities in northern Sierra Leone, a baseline study to inform Ebola vaccine study protocols

PLoS ONE(2022)10.1371/journal.pone.0270968

N/A

0DataRank · unranked

11 citations

Suzanne Fleck, Bailah Leigh, Philip Ayieko, Daniel Tindanbil, Tuda Otieno +12 more

Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries

(2020)10.21203/rs.3.rs-30774/v1

N/A

0DataRank · unranked

0 citations

Édouard Lhomme, Mark Kieh, Abdoul Habib Béavogui, Stephen B. Kennedy, Seydou Doumbia +20 more

Immunogenicity and Safety of One-Dose Human Papillomavirus Vaccine Compared With Two or Three Doses in Tanzanian Girls (DoRIS): An Open-Label, Randomised, Non-inferiority Trial

Obstetrical & Gynecological Survey(2023)10.1097/ogx.0000000000001135

N/A

0DataRank · unranked

1 citations

John Changalucha, Hilary Whitworth, Lígia A. Pinto, Paul Mutani, Jackton Indangasi +18 more

Comparing one dose of HPV vaccine in girls aged 9–14 years in Tanzania (DoRIS) with one dose in young women aged 15–20 years in Kenya (KEN SHE): an immunobridging analysis of randomised controlled trials

The Lancet Global Health(2024)10.1016/s2214-109x(23)00586-7

N/A

0DataRank · unranked

42 citations

Troy J. Kemp, Nelly Mugo, Hilary Whitworth, Maricianah Onono, Betty Njoroge +14 more

Associations between HIV stigma and health-related quality-of-life among people living with HIV: cross-sectional analysis of data from HPTN 071 (PopART)

Scientific Reports(2024)10.1038/s41598-024-63216-3

N/A

0DataRank · unranked

9 citations

Katherine Davis, Julius Ohrnberger, Michael Pickles, Simon Gregson, Ranjeeta Thomas +58 more

Single-dose human papillomavirus vaccination: an update

JNCI Monographs(2024)10.1093/jncimonographs/lgae030

N/A

0DataRank · unranked

8 citations

Deborah Watson‐Jones, Jane J. Kim, Peter Dull, Aimée R. Kreimer